Clear All
765 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
Q5114 Trastuzumab-dkst Ogivri 10mg Immunotherapy Monoclonal Antibody HER2 No 2017 Jul 1, 2019 In Use
C9472 Talimogene Laherparepvec Imlygic 1 million plaque forming unites (PFU) Immunotherapy Therapeutic Cancer Vaccine Oncolytic Virus No 2015 Apr 1, 2016 In Use
C9292 Pertuzumab Perjeta 10 mg Immunotherapy Monoclonal Antibody HER2 No 2012 Oct 1, 2012 Dec 31, 2013 No Longer Used
J9303 Panitumumab Vectibix 10mg Immunotherapy Monoclonal Antibody EGFR No 2006 Jan 1, 2008 In Use
C9306 Telisotuzumab vedotin-tllv Emrelis 1mg Immunotherapy Drug Antibody Conjugate c-MET No 2025 Sep 8, 2025 In Use
C9076 Lisocabtagene maraleucel Breyanzi Immunotherapy CAR-T CD19 No 2021 Jul 23, 2021 Sep 27, 2021 No Longer Used
C9073 Brexucabtagene autileucel Tecartus 2000000 Immunotherapy CAR-T CD19 No 2020 Jan 1, 2021 Apr 1, 2021 In Use
J9353 Margetuximab-cmkb Margenza 5mg Immunotherapy Monoclonal Antibody HER2 No 2021 Jul 23, 2021 In Use
J9306 Pertuzumab Perjeta 1 mg Immunotherapy Monoclonal Antibody HER2 No 2012 Jan 1, 2014 In Use
J9145 Daratumumab Darzalex 10 mg Immunotherapy Monoclonal Antibody CD38 No 2015 Jan 1, 2017 In Use
J9311 Rituximab and Hyaluronidase Rituxan Hycela 10mg Immunotherapy Monoclonal Antibody CD20 No 2017 Jan 1, 2019 In Use
J9274 Tebentafusp-tebn Kimmtrak 1mcg Immunotherapy T Cell Receptor (TCR) HLA-A*02:01 No 2022 Sep 27, 2022 In Use
C9416 BCG BCG, Intravesical Per instillation Immunotherapy Biological Response Modifier Live Vaccine No 1990 Jan 1, 2004 Dec 31, 2003 No Longer Used
J9055 Cetuximab Erbitux 10 mg Immunotherapy Monoclonal Antibody EGFR No 2004 Jan 1, 2005 In Use
J9355 Trastuzumab Herceptin 10 mg Immunotherapy Monoclonal Antibody HER2 No 1998 Jan 1, 2000 In Use
J9308 Ramucirumab Cyramza 5mg Immunotherapy Monoclonal Antibody VEGFR No 2014 Jan 1, 2016 In Use
Q2054 Lisocabtagene maraleucel Breyanzi Immunotherapy CAR-T CD19 No 2021 Sep 27, 2021 In Use
J9295 Necitumumab Portrazza 1 mg Immunotherapy Monoclonal Antibody EGFR No 2015 Jan 1, 2017 In Use
J9037 Belantamab mafodontin-blmf Blenrep 0.5mg Immunotherapy Drug Antibody Conjugate BCMA No 2020 Apr 1, 2021 Mar 26, 2025 No Longer Used
J9302 Ofatumumab Arzerra 10mg Immunotherapy Monoclonal Antibody CD20 No 2009 Jan 1, 2011 In Use
J9316 Pertuzumab, Trastuzumab, Hyaluronidase-zzxf Phesgo 10mg Immunotherapy Monoclonal Antibody HER2 No 2020 Jan 1, 2021 In Use
Q5112 Trastuzumab-dttb Ontruzant 10mg Immunotherapy Monoclonal Antibody HER2 No 2021 Jul 1, 2019 In Use
J1326 Zolbetuximab-clzb Vyloy 2mg Immunotherapy Monoclonal Antibody CLDN18.2 No 2024 Jul 9, 2025 In Use
NA Pomalidomide Pomalyst 4 mg Immunotherapy Immunomodulator Thalidomide Analog Yes 2013 In Use
S0145 Pegintereferon Alfa-2a Pegasys 180 mcg/mL Immunotherapy Cytokine Interferon No 2002 Jul 1, 2005 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.